Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057706 | 0.87 | RECQL (0.36) | ALDH1A1LMNACYP2C19CYP3A4MAPT | |
| SCHEMBL21057816 | 0.85 | TP53 (0.44) | ALDH1A1CYP2C19CYP3A4MAPTCYP2C9 | |
| SCHEMBL21057764 | 0.85 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL24378247 | 0.85 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL21057760 | 0.84 | RECQL (0.46) | ALDH1A1RECQL | |
| SCHEMBL21057704 | 0.84 | CYP2C19 (0.42) | ALDH1A1PKMLMNACYP2C19TDP1 | |
| SCHEMBL21057707 | 0.84 | CYP2C19 (0.42) | ALDH1A1PKMLMNACYP2C19TDP1 | |
| SCHEMBL24282688 | 0.84 | CYP2C19 (0.42) | ALDH1A1PKMLMNACYP2C19TDP1 | |
| SCHEMBL21057709 | 0.84 | CYP2C19 (0.42) | ALDH1A1PKMLMNACYP2C19TDP1 | |
| SCHEMBL21057955 | 0.84 | CYP2D6 (0.50) | ALDH1A1LMNACYP2C19CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3728219-B1 | SUBSTITUTED PYRROLIDINE AMIDES I | GRUENENTHAL GMBH (DE) | 2022-04-13 | — | — | EP | disclosed |
| EP-3728233-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3728219-A1 | SUBSTITUTED PYRROLIDINE AMIDES I | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111556867-A | Substituted pyrrolidine amides I | 格吕伦塔尔有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-111491931-A | Substituted pyrrolidine amides II | 格吕伦塔尔有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-10626106-B2 | Substituted pyrrolidine amides I | GRUENENTHAL GMBH (DE) | 2020-04-21 | — | — | US | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185470-A1 | Substituted Pyrrolidine Amides II | NR3C1, NR3C2, MC2R | ALDH1A1 1258/4885PKM 1425/4885LMNA 4704/4885 |
| US-10626106-B2 | Substituted pyrrolidine amides I | NR3C1, NR3C2, NR5A1 | ALDH1A1 814/4885PKM 1315/4885LMNA 4685/4885 |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | NR3C1, NR3C2, MC2R | ALDH1A1 1258/4885PKM 1425/4885LMNA 4704/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | ALDH1A1 1258/4885PKM 1425/4885LMNA 4704/4885 |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | NR3C1, NR3C2, NR5A1 | ALDH1A1 814/4885PKM 1315/4885LMNA 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.